A Framework for Successful Intrathecal Pain Management: New Insights from the 2017 Polyanalgesic Consensus Conference (PACC) Guidelines
Click Here To Download Device Size - Emergency Resource (PDF)
Click Here To Download - Max Dose - Pocket Resource (PDF)
Click Here To Download - Starting Dose - Pocket Resource (PDF)
Click Here To Download Trialing - Pocket Resource (PDF)
neuroscienceCME Webcast
Premiere Date: Tuesday, April 18, 2017This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, April 18, 2018
Note: Credit Is No Longer Available
 | Gladstone C. McDowell II, MD Medical Director Integrated Pain Solutions Columbus, OH |
 | Jason E. Pope, MD, DABPM, FIPP President Summit Pain Alliance Santa Rosa, CA |
Once perceived to be a management approach reserved for salvage therapy—the final straw—after failure of oral high dose opioids, intrathecal drug delivery (IDD) has been established as a cost-effective and efficacious pain management strategy for patients with refractory chronic pain. As the use of IDD expands, there is a need to reduce variability among health care providers in medications that are used, patient selection, trialing, and dosing in order to improve safety and patient outcomes.
In 2000, the Polyanalgesic Consensus Conference (PACC) was formed to provide guidance and recommendations to physicians utilizing IDD to promote safe and effective therapy for patients with refractory chronic pain. As new devices were introduced, new evidence emerged, and experience with intrathecal (IT) therapy expanded—identifying both deficiencies and opportunities—the PACC guidelines were updated. On January 2, 2017, the updated PACC: Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines were released.
Join CME Outfitters for this 60-minute symposium as expert faculty translate the new PACC guidelines for use in clinical practice.
At the end of this CE activity, participants should be able to:
- Translate updates and recommendations in the 2017 PACC guidelines to clinical decision-making for patients with refractory chronic pain who are candidates for intrathecal (IT) therapy.
- Apply PACC recommendations for trialing of appropriate patients who are candidates for IT therapy.
- Implement dosing and titration strategies in patients utilizing IDD to maximize results while mitigating risks.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Explain updates and recommendations in the 2017 PACC guidelines for patients with refractory chronic pain who are candidates for intrathecal (IT) therapy.
- Identify PACC recommendations for trialing of appropriate patients who are candidates for IT therapy.
- Describe dosing and titration strategies in patients utilizing IDD to maximize results while mitigating risks.
Supported by an educational grant from Jazz Pharmaceuticals, Inc.
Pain physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare providers treating patients with chronic pain.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1 contact hour
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1 contact hour of pharmacotherapeutic contact hour.
Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTM through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)TM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1 contact hour (0.10 CEU) Universal Activity Number:
0376-0000-17-007-H01-P
Type: knowledge-based
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST21244 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. McDowell reports that he receives research support from Flowonix Medical Inc.; Jazz Pharmaceuticals; Mallinckrodt Pharmaceuticals; and Medtronic. He serves on the speakers bureau for Jazz Pharmaceuticals and Medtronic. He is a consultant for Flowonix Medical Inc. and Jazz Pharmaceuticals.
Dr. Pope reports that he receives research support from Abbott; Flowonix Medical Inc.; Jazz Pharmaceuticals; Mesoblast Limited; Nevro Corp.; and Saluda Medical. He is a consultant for Abbott; Flowonix Medical Inc.; Jazz Pharmaceuticals; Medtronic; Nevro Corp.; and Saluda Medical.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Kimberley Murray, RN, MS (peer reviewer) has no disclosures to report.
Sharon Tordoff, CHCP (planning committee) has no disclosures to report.
Jan Perez, CHCP (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MMV-072-041817
